CXCL10 and metabolic dysfunction-associated steatotic liver disease: In the present study, we observed that YLZD reversed the expression levels of TNF-α, IL-6, IL-1β, and NF-κB in liver tissues of NAFLD rats and decreased the expression of inflammatory chemokines CCL2 and CXCL10.